IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
49.65
-1.37 (-2.69%)
At close: 4:00PM EDT

49.82 +0.17 (0.34%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close51.02
Open50.72
Bid49.52 x 1000
Ask49.71 x 1000
Day's Range49.11 - 50.92
52 Week Range39.07 - 65.51
Volume842,284
Avg. Volume916,251
Market Cap6.816B
Beta3.28
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.50
Trade prices are not sourced from all markets
  • Akcea Therapeutics Soars as It Readies Its First Drug Launch
    Motley Fool3 hours ago

    Akcea Therapeutics Soars as It Readies Its First Drug Launch

    But the real opportunity may be with Ionis Pharmaceuticals.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit8 hours ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on August 13.

  • Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses
    Motley Fool2 days ago

    Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses

    It's hard to make a profit that way, but the situation seems temporary as the biotech waits for FDA approval of two drugs.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool2 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.

  • Why Biogen's Stock Ripped Higher in July
    Motley Fool4 days ago

    Why Biogen's Stock Ripped Higher in July

    Biogen's stock got a boost from two material events last month.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist6 days ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending June 30, 2018.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist6 days ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • What Analysts Recommend for Ionis after Q2 2018
    Market Realist6 days ago

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017. Also, the company is estimated to report a net adjusted loss of $29.9 million during 2018 as compared to a net adjusted loss of $5.9 million during 2017, following the increase in selling, general, and administrative expenses as well as research and development expenses. The adjusted earnings per share for 2018 are estimated to come in at -$0.08 per share.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist7 days ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist7 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • How Ionis’s Q2 2018 Earnings Trended
    Market Realist7 days ago

    How Ionis’s Q2 2018 Earnings Trended

    Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.

  • Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks8 days ago

    Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates

    Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -150.00% and -8.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press8 days ago

    Ionis Pharmaceuticals: 2Q Earnings Snapshot

    The Carlsbad, California-based company said it had a loss of 29 cents per share. Losses, adjusted for non-recurring costs, were 5 cents per share. The results fell short of Wall Street expectations. The ...

  • Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss
    Zacks8 days ago

    Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss

    Ionis posts wider than expected loss and sales miss estimates in the second quarter of 2018.

  • ACCESSWIRE8 days ago

    Ionis Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 11:30 AM Eastern ...

  • PR Newswire8 days ago

    Ionis Reports Second Quarter 2018 Financial Results

    Year-to-date revenues increased 15%, driven by increased SPINRAZA revenue TEGSEDI approved and on track to launch in the EU Positive FDA Advisory Committee vote recommending approval of WAYLIVRA Conference ...

  • GlobeNewswire9 days ago

    Akcea Reports Financial Results and Highlights for Second Quarter 2018

    TEGSEDI™ Approved in European Union $382 million to fund the company through key milestones in 2019. Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com. CAMBRIDGE, Mass., Aug. 06, ...

  • Alnylam Pharmaceuticals Is "Launch Ready"
    Motley Fool9 days ago

    Alnylam Pharmaceuticals Is "Launch Ready"

    Now it just needs regulators to sign off on its marketing applications.

  • Analysts Have Mixed Opinions about Ionis
    Market Realist9 days ago

    Analysts Have Mixed Opinions about Ionis

    What Do Analysts Expect from Ionis’s Second-Quarter Earnings? Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017. Ionis’s stock price has decreased by nearly 14.5% over the last 12 months and decreased by ~14.3% in 2018 year-to-date.

  • What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
    Market Realist9 days ago

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Short interest is moderately high for IONS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold IONS had net inflows of $2.32 billion over the last one-month.

  • InvestorPlace12 days ago

    Avoid Treating Biogen Like a Speculative Drug Stock

    Biogen (NASDAQ:BIIB) stock has come down from its recent high. A successful Phase 2 trial of an Alzheimer’s drug sent BIIB stock soaring. Although a successful Phase 3 trial could send BIIB stock soaring to new highs, such an achievement is by no means a sure thing.

  • Bluebird Bio Misses Analysts’ Estimates in Q2 2018
    Market Realist12 days ago

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.